RT Journal Article SR Electronic T1 Is there a place for ▼duloxetine? JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 29 OP 32 DO 10.1136/dtb.2007.45429 VO 45 IS 4 YR 2007 UL http://dtb.bmj.com/content/45/4/29.abstract AB Relevant BNF sections: 4.3.4, 6.1.5▼Duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, is licensed in the UK under two brand names for a total of three different indications. It is available as Cymbalta (jointly promoted by Boehringer Ingelheim and Lilly) for the treatment of patients with major depression, or with diabetic peripheral neuropathic pain; and as Yentreve (Lilly) for the treatment of women with “moderate to severe” stress urinary incontinence. Here we consider whether duloxetine has a role in the treatment of patients with any of these conditions.